Last updated: 2026-10-12 22:44:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Arrowhead Research Corporation (ARWR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $60.77, with a market capitalisation of $8.86B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $34.61 to $95.49. This page covers its latest market performance, valuation, price trends and company information.
$8.86B | |
$62.49 | |
$95.49 | |
$1.20 | |
$62.75 | |
899.79K | |
1.90M | |
-- | |
$95.49 | |
$34.61 | |
-- | |
-- |
Arrowhead Research Corporation (ARWR) is trading at $61.71 in after-hours trading as of 2026-10-12 22:17:00, down 1.66% ($1.04) from the regular-session close of $62.75.
After-hours trading shows how investors are pricing ARWR after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Arrowhead Research Corporation (ARWR) moved from $64.79 to $60.77, representing a decline of 6.21% ($4.03).
The stock traded between $59.21 and $66.16 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.90 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 43.0%
ARWR is currently trading at $60.77, placing it 43.0% of the way from its 52-week low of $34.61 to its 52-week high of $95.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 711 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arrowhead Research Corporation (ARWR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.